Abstract:BackgroundThe G-protein coupled receptor (GPCR) superfamily is currently the largest class of therapeutic targets. In silico prediction of interactions between GPCRs and small molecules in the transmembrane ligand-binding site is therefore a crucial step in the drug discovery process, which remains a daunting task due to the difficulty to characterize the 3D structure of most GPCRs, and to the limited amount of known ligands for some members of the superfamily. Chemogenomics, which attempts to characterize interactions between all members of a target class and all small molecules simultaneously, has recently been proposed as an interesting alternative to traditional docking or ligand-based virtual screening strategies.ResultsWe show that interaction prediction in the chemogenomics framework outperforms state-of-the-art individual ligand-based methods in accuracy both for receptor with known ligands and without known ligands. This is done with no knowledge of the receptor 3D structure. In particular we are able to predict ligands of orphan GPCRs with an estimated accuracy of 78.1%.ConclusionWe propose new methods for in silico chemogenomics and validate them on the virtual screening of GPCRs. The methods represent an extension of a recently proposed machine learning strategy, based on support vector machines (SVM), which provides a flexible framework to incorporate various information sources on the biological space of targets and on the chemical space of small molecules. We investigate the use of 2D and 3D descriptors for small molecules, and test a variety of descriptors for GPCRs. We show that incorporating information about the known hierarchical classification of the target family and about key residues in their inferred binding pockets significantly improves the prediction accuracy of our model.

Computational Screening for Active Compounds Targeting Protein Sequences: Methodology and Experimental Validation

Virtual Screening on Natural Products for Discovering Active Compounds and Target Information

A support vector machines approach for virtual screening of active compounds of single and multiple mechanisms from large libraries at an improved hit-rate and enrichment factor

Current Advances in Ligand‐based Target Prediction

In silico prediction of drug-target interaction networks based on drug chemical structure and protein sequences

Molecular docking-based computational platform for high-throughput virtual screening

Prediction of Bioactive Compound Pathways Using Chemical Interaction and Structural Information.

In-silico Target Prediction by Ensemble Chemogenomic Model Based on Multi-Scale Information of Chemical Structures and Protein Sequences.

DrugMGR: a deep bioactive molecule binding method to identify compounds targeting proteins

Virtual screening of GPCRs: An in silico chemogenomics approach

Improved genome-scale multi-target virtual screening via a novel collaborative filtering approach to cold-start problem

SVSBI: Sequence-based virtual screening of biomolecular interactions

Integrating Machine Learning-Based Virtual Screening With Multiple Protein Structures and Bio-Assay Evaluation for Discovery of Novel GSK3β Inhibitors

Development and Experimental Test of Support Vector Machines Virtual Screening Method for Searching Src Inhibitors from Large Compound Libraries.

Computational Strategy for Bound State Structure Prediction in Structure-Based Virtual Screening: A Case Study of Protein Tyrosine Phosphatase Receptor Type O Inhibitors

Prediction of Chemical-Protein Interactions: Multitarget-Qsar Versus Computational Chemogenomic Methods

Virtual Screening and Molecular Docking: Discovering Novel METTL3 Inhibitors

Consensus holistic virtual screening for drug discovery: a novel machine learning model approach

Combined Svm-Based and Docking-Based Virtual Screening for Retrieving Novel Inhibitors of C-Met

Reducing false positive rate of docking-based virtual screening by active learning

SHAFTS: a hybrid approach for 3D molecular similarity calculation. 2. Prospective case study in the discovery of diverse p90 ribosomal S6 protein kinase 2 inhibitors to suppress cell migration.